This company listing is no longer active
MYXDA Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$3.54 |
52 Week High | AU$4.00 |
52 Week Low | AU$3.30 |
Beta | 1.02 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -9.23% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
MYXDA | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -9.2% | 4.0% | 2.0% |
1Y | n/a | 51.3% | 9.5% |
Return vs Industry: Insufficient data to determine how MYXDA performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MYXDA performed against the Australian Market.
Price Volatility
MYXDA volatility | |
---|---|
MYXDA Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.4% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MYXDA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MYXDA's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
MYXDA fundamental statistics | |
---|---|
Market cap | AU$305.36m |
Earnings (TTM) | -AU$263.34m |
Revenue (TTM) | AU$424.80m |
0.7x
P/S Ratio-1.2x
P/E RatioIs MYXDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MYXDA income statement (TTM) | |
---|---|
Revenue | AU$424.80m |
Cost of Revenue | AU$253.77m |
Gross Profit | AU$171.03m |
Other Expenses | AU$434.37m |
Earnings | -AU$263.34m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Feb 23, 2023
Earnings per share (EPS) | -3.07 |
Gross Margin | 40.26% |
Net Profit Margin | -61.99% |
Debt/Equity Ratio | 72.8% |
How did MYXDA perform over the long term?
See historical performance and comparison